Mark Breidenbach
Stock Analyst at Oppenheimer
(4.22)
# 528
Out of 4,413 analysts
55
Total ratings
39.68%
Success rate
23.68%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $6.62 | +156.80% | 4 | Dec 13, 2023 | |
| ALPN Alpine Immune Sciences | Maintains: Outperform | $14 → $22 | $64.60 | -65.94% | 4 | Sep 11, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $32.48 | +192.49% | 5 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $1.53 | +1,533.99% | 3 | Aug 8, 2023 | |
| ALLO Allogene Therapeutics | Reiterates: Outperform | $28 | $2.92 | +858.90% | 4 | Aug 3, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $1.91 | +424.93% | 5 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $12 | $1.08 | +1,011.11% | 4 | Jun 26, 2023 | |
| NRIX Nurix Therapeutics | Assumes: Outperform | $25 | $13.08 | +91.13% | 2 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $4 | $0.67 | +495.24% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.99 | +251.76% | 6 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $3.69 | +767.21% | 2 | Mar 10, 2023 | |
| SYRS Syros Pharmaceuticals | Maintains: Outperform | $15 → $13 | $5.44 | +138.97% | 3 | Mar 3, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $12.50 | +20.00% | 5 | Mar 1, 2023 | |
| SYBX Synlogic | Maintains: Outperform | $90 → $120 | $1.90 | +6,215.79% | 3 | Oct 18, 2022 | |
| ACHL Achilles Therapeutics | Initiates: Outperform | n/a | $0.78 | - | 1 | Apr 26, 2021 | |
| BLUE bluebird bio | Upgrades: Outperform | n/a | $0.91 | - | 2 | Dec 13, 2019 | |
| MBIO Mustang Bio | Initiates: Outperform | n/a | $0.26 | - | 1 | Dec 21, 2017 |
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $6.62
Upside: +156.80%
Alpine Immune Sciences
Sep 11, 2023
Maintains: Outperform
Price Target: $14 → $22
Current: $64.60
Upside: -65.94%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $32.48
Upside: +192.49%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $1.53
Upside: +1,533.99%
Allogene Therapeutics
Aug 3, 2023
Reiterates: Outperform
Price Target: $28
Current: $2.92
Upside: +858.90%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $1.91
Upside: +424.93%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $12
Current: $1.08
Upside: +1,011.11%
Nurix Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $25
Current: $13.08
Upside: +91.13%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.67
Upside: +495.24%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.99
Upside: +251.76%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $3.69
Upside: +767.21%
Syros Pharmaceuticals
Mar 3, 2023
Maintains: Outperform
Price Target: $15 → $13
Current: $5.44
Upside: +138.97%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $12.50
Upside: +20.00%
Synlogic
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.90
Upside: +6,215.79%
Achilles Therapeutics
Apr 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.78
Upside: -
bluebird bio
Dec 13, 2019
Upgrades: Outperform
Price Target: n/a
Current: $0.91
Upside: -
Mustang Bio
Dec 21, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.26
Upside: -